Patients with bladder cancer being treated with the immunotherapy agent, Keytruda, should not hesitate to call their oncology team if something does not feel right, an expert said. Patients with ...
Keytruda did not significantly impact long-term health-related quality of life in stage 3 melanoma patients compared to placebo. Both Keytruda and placebo groups returned to baseline quality of life ...
Instead of attacking cancer directly, these treatments, including nivolumab (Opdivo) and pembrolizumab (Keytruda), keep your immune system active to help it recognize and destroy cancer cells more ...
On Thursday, Merck & Co Inc (NYSE:MRK) announced discontinuing the Phase 3 KeyVibe-008 trial based on an independent Data Monitoring Committee (DMC) recommendation. The trial is evaluating the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results